Advantage of the F2:A1:B- IncF Pandemic Plasmid over IncC Plasmids in

Anti-Bacterial Agents / pharmacology Cefotaxime / pharmacology Escherichia coli / drug effects Microbial Sensitivity Tests Mutation / genetics Plasmids / genetics beta-Lactamases / genetics
CTX-M-15, Escherichia coli ST131 IncC plasmid IncF plasmid experimental evolution extended-spectrum beta-lactamase fitness cost

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
10 2019
Historique:
received: 04 06 2019
accepted: 09 07 2019
pubmed: 25 7 2019
medline: 4 8 2020
entrez: 24 7 2019
Statut: epublish

Résumé

Despite a fitness cost imposed on bacterial hosts, large conjugative plasmids play a key role in the diffusion of resistance determinants, such as CTX-M extended-spectrum β-lactamases. Among the large conjugative plasmids, IncF plasmids are the most predominant group, and an F2:A1:B- IncF-type plasmid encoding a CTX-M-15 variant was recently described as being strongly associated with the emerging worldwide

Identifiants

DOI: 10.1128/AAC.01130-19 PMID: 31332067 PMC: PMC6761558
pubmed: 31332067
pii: AAC.01130-19
doi: 10.1128/AAC.01130-19
pmc: PMC6761558
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-lactamase CTX-M-15 EC 3.5.2.-
beta-Lactamases EC 3.5.2.6
Cefotaxime N2GI8B1GK7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 Mahérault et al.

Références

Nat Commun. 2014 Oct 10;5:5208
pubmed: 25302567
Annu Rev Microbiol. 2007;61:71-87
pubmed: 17447862
J Antimicrob Chemother. 2017 Aug 1;72(8):2145-2155
pubmed: 28541467
Nat Ecol Evol. 2017 Sep;1(9):1354-1363
pubmed: 29046540
Mol Microbiol. 2006 May;60(4):820-7
pubmed: 16677295
BMC Microbiol. 2012 Apr 04;12:53
pubmed: 22475035
Methods Mol Biol. 2014;1151:165-88
pubmed: 24838886
Trends Microbiol. 2012 Jun;20(6):262-7
pubmed: 22564249
Antimicrob Agents Chemother. 2006 Sep;50(9):3003-10
pubmed: 16940095
Mol Biol Evol. 2016 Nov;33(11):2860-2873
pubmed: 27501945
BMC Genomics. 2008 Nov 26;9:560
pubmed: 19036134
J Antimicrob Chemother. 2010 Dec;65(12):2518-29
pubmed: 20935300
J Antimicrob Chemother. 2007 Feb;59(2):165-74
pubmed: 17158117
Nature. 1988 Sep 22;335(6188):351-2
pubmed: 3047585
Brief Bioinform. 2019 Jul 19;20(4):1071-1084
pubmed: 28968784
Antimicrob Agents Chemother. 2011 Nov;55(11):4971-8
pubmed: 21859935
Clin Microbiol Rev. 2015 Jul;28(3):565-91
pubmed: 25926236
Biotechnol Bioeng. 2003 Jan 20;81(2):178-86
pubmed: 12451554
Antimicrob Agents Chemother. 2004 Jan;48(1):1-14
pubmed: 14693512
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8587-91
pubmed: 2172991
Clin Microbiol Rev. 2013 Oct;26(4):744-58
pubmed: 24092853
J Antimicrob Chemother. 2005 Jul;56(1):52-9
pubmed: 15917288
Curr Biol. 2015 Aug 3;25(15):2034-9
pubmed: 26190075
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27872077
J Antimicrob Chemother. 2005 Sep;56(3):544-51
pubmed: 16040624
BMC Microbiol. 2017 Mar 27;17(1):71
pubmed: 28347271
J Gen Microbiol. 1990 Nov;136(11):2319-25
pubmed: 2079626
Sci Rep. 2016 Dec 13;6:38828
pubmed: 27958314
Clin Microbiol Infect. 2014 May;20(5):380-90
pubmed: 24766445
J Antimicrob Chemother. 2018 May 1;73(5):1121-1137
pubmed: 29370371
PLoS Genet. 2011 Jul;7(7):e1002181
pubmed: 21829372
mBio. 2016 Mar 22;7(2):e02162
pubmed: 27006459
Microb Genom. 2018 Sep;4(9):
pubmed: 30080134
J Antimicrob Chemother. 2008 Feb;61(2):273-81
pubmed: 18077311
Genes Dev. 2006 Apr 1;20(7):884-97
pubmed: 16600914
mSphere. 2016 Jun 29;1(4):
pubmed: 27390780
mSphere. 2018 Jan 31;3(1):
pubmed: 29404421
PLoS Genet. 2014 Oct 02;10(10):e1004649
pubmed: 25275371
Biol Lett. 2005 Jun 22;1(2):250-2
pubmed: 17148179
Mol Biol Evol. 2016 Apr;33(4):885-97
pubmed: 26668183
Emerg Infect Dis. 2008 Feb;14(2):195-200
pubmed: 18258110
Plasmid. 2019 Mar;102:29-36
pubmed: 30771401
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27956424
Antimicrob Agents Chemother. 2012 May;56(5):2763-6
pubmed: 22330911
mBio. 2015 Jun 09;6(3):e00762
pubmed: 26060276
Nat Commun. 2017 Nov 22;8(1):1689
pubmed: 29162798
mBio. 2014 Oct 07;5(5):e01801-14
pubmed: 25293759
Genetics. 2003 Dec;165(4):1641-9
pubmed: 14704155
Genetics. 2008 Apr;178(4):2179-90
pubmed: 18430943
mBio. 2015 Dec 08;6(6):e01866-15
pubmed: 26646012
J Antimicrob Chemother. 2013 Oct;68(10):2259-62
pubmed: 23711894
J Antimicrob Chemother. 2009 Jan;63(1):67-71
pubmed: 18931389
J Bacteriol. 2012 Jul;194(14):3742-3
pubmed: 22740669
Science. 2003 Sep 12;301(5639):1496-9
pubmed: 12970556
Korean J Intern Med. 2012 Jun;27(2):128-42
pubmed: 22707882
Appl Environ Microbiol. 2015 May 15;81(10):3561-70
pubmed: 25769824
ISME J. 2014 Mar;8(3):601-612
pubmed: 24152711
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5694-9
pubmed: 24706808
mSphere. 2016 Apr 06;1(2):
pubmed: 27303727
Mob Genet Elements. 2012 Jan 1;2(1):55-58
pubmed: 22754754
Appl Environ Microbiol. 2011 Jul;77(13):4486-93
pubmed: 21602382
Genetics. 2007 Jun;176(2):957-68
pubmed: 17151258
FEMS Microbiol Rev. 2011 Sep;35(5):820-55
pubmed: 21564142
FEMS Microbiol Rev. 2011 Sep;35(5):901-11
pubmed: 21707669
Int J Med Microbiol. 2011 Dec;301(8):654-8
pubmed: 21992746
Plasmid. 2015 Jul;80:63-82
pubmed: 25910948
J Bacteriol. 1994 Jun;176(11):3140-7
pubmed: 8195066
Int J Antimicrob Agents. 2010 Apr;35(4):316-21
pubmed: 20060273
mBio. 2018 Apr 24;9(2):
pubmed: 29691332
Plasmid. 2018 Mar - May;96-97:7-12
pubmed: 29486211
Antimicrob Agents Chemother. 2009 Jun;53(6):2227-38
pubmed: 19307361
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391

Auteurs

Anne-Claire Mahérault (AC)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.
AP-HP, Laboratoire de Microbiologie Hygiène, Hôpital Louis Mourier, Colombes, France.

Harry Kemble (H)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

Mélanie Magnan (M)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

Benoit Gachet (B)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

David Roche (D)

Laboratoire d'Analyse Bioinformatique en Génomique et Métabolisme, Institut de Génomique, Commissariat à l'Energie Atomique, Génoscope, CNRS-UMR 8030, Evry, France.

Hervé Le Nagard (H)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

Olivier Tenaillon (O)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

Erick Denamur (E)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.
AP-HP, Laboratoire de Génétique Moléculaire, Hôpital Bichat, Paris, France.

Catherine Branger (C)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France.

Luce Landraud (L)

Université de Paris, IAME, UMR 1137, INSERM, Paris, France luce.landraud@aphp.fr.
AP-HP, Laboratoire de Microbiologie Hygiène, Hôpital Louis Mourier, Colombes, France.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee et al.
1.00
T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfacétrile › Céfotaxime › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Plasmides › Advantage of the F2:A1:B- IncF Pandemic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › bêta-Lactamases › Advantage of the F2:A1:B- IncF Pandemic...